Validation of a care and comfort hypertonicity questionnaire

Developmental Medicine and Child Neurology

Volumn 48, Issue 3, 2006, Pages 181-187

  McCoy, Robin Nemer ^a   Blasco, Peter A ^a,b,d   Russman, Barry S ^b,c   O'Malley, Jean P ^c  

^a OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^b SHRINERS HOSPITAL FOR CHILDREN   (United States)

^c OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^d OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BACLOFEN; BOTULINUM TOXIN A; MUSCLE RELAXANT AGENT;

ADOLESCENT; ADULT; ARTICLE; CAREGIVER; CEREBRAL PALSY; CHILD; CLINICAL ARTICLE; CLINICAL PROTOCOL; CONTROLLED STUDY; DISEASE SEVERITY; DOCUMENTATION; DORSAL RHIZOTOMY; DYSTONIA; FEMALE; HUMAN; MALE; MEDICAL DOCUMENTATION; MEDICAL RECORD REVIEW; METHODOLOGY; MOTOR PERFORMANCE; MUSCLE HYPERTONIA; MUSCLE SPASM; MUSCLE TONE; ORTHOPEDIC SURGERY; PATIENT CARE; PATIENT REFERRAL; PRIORITY JOURNAL; QUESTIONNAIRE; RATING SCALE; STATISTICAL SIGNIFICANCE; THERAPY EFFECT; VALIDATION STUDY; VALIDITY; DEMOGRAPHY; HOSPITALIZATION; INTRAMUSCULAR DRUG ADMINISTRATION; PRESCHOOL CHILD; REPRODUCIBILITY; REST;

ADOLESCENT; ADULT; BOTULINUM TOXIN TYPE A; CEREBRAL PALSY; CHILD; CHILD, PRESCHOOL; DEMOGRAPHY; FEMALE; HUMANS; INJECTIONS, INTRAMUSCULAR; MALE; MUSCLE HYPERTONIA; NEUROMUSCULAR AGENTS; PATIENT CARE; QUESTIONNAIRES; REPRODUCIBILITY OF RESULTS; REST; SEVERITY OF ILLNESS INDEX;

EID: 33645751086     PISSN: 00121622     EISSN: 14698749     Source Type: Journal    
DOI: 10.1017/S0012162206000405     Document Type: Article

References (33)

1. Abbott R. (1996) Sensory rhizotomy for the treatment of childhood spasticity. J Child Neurol 11(Suppl. 1): S36-S42.
2. Albright AL. (1996) Intrathecal baclofen in cerebral palsy movement disorders. J Child Neurol 11(Suppl. 1): S29-S35.
3. Albright AL, Barron WB, Fasick MP, Polinko P, Janosky J. (1993) Continuous intrathecal baclofen infusion for spasticity of cerebral origin. JAMA 270: 2475-2477.
4. Albright AL, Cervi A, Singletary J. (1991) Intrathecal baclofen for spasticity in cerebral palsy. JAMA 265: 1418-1422.
5. Armstrong RW, Steinbok P, Cochrane DD, Kube SD, Fife SE, Farrell K. (1997) Intrathecally administered baclofen for treatment of children with spasticity of cerebral origin. J Neurosurg 87: 409-414.
6. Bjornson KF, McLaughlin JF. (2001) The measurement of health-related quality of life (HRQL) in children with cerebral palsy. Eur J Neurol 8 (Suppl. 5): 183-193.
7. Bjornson KF, McLaughlin JF, Loeser JD, Nowak-Cooperman KM, Russel M, Bader KA, Desmond SA. (2003) Oral motor, communication, and nutritional status of children during intrathecal baclofen therapy: A descriptive pilot study. Arch Phys Med Rehabil 84: 500-506.
8. Bohannon RW, Smith MB. (1987) Interrater reliability of a modified Ashworth scale of muscle spasticity. Phys Ther 67: 206-207.
9. Butter C, Campbell S. (2000) Evidence of the effects of intrathecal baclofen for spastic and dystonic cerebral palsy. AACPDM Treatment Outcomes Committee Review Panel. Dev Med Child Neurol 42: 634-645.
10. Dralle D, Muller H, Zierski J, Klug N. (1985) Intrathecal baclofen for spasticity. Lancet 2: 1003.
11. Feldman BG, Grundland B, McCullough L, Wright V. (2000) Distinction of quality of life, health related quality of life and health status in children referred for rheumatologic care. J Rheumatol 27: 226-233.
12. Gianino JM, York MM, Paice JA, Shott S. (1998) Quality of life: Effect of reduced spasticity from intrathecal baclofen. J Neurosci Nurs 30: 47-54.
13. Gilmartin R, Bruce D, Storrs BB, Abbott R, Krach L, Ward J, Bloom K, Brooks WH, Johnson DL, Madsen JR, McLaughlin JF, Nadell J. (2000) Intrathecal baclofen for management of spastic cerebral palsy: multicenter trial. J Child Neurol 15: 71-77.
14. Gooch JL, Oberg WA, Grams B, Ward LA, Walker ML. (2004) Care provider assessment of intrathecal baclofen in children. Dev Med Child Neurol 46: 548-552.
15. Graham HK, Aoki KR, Autti-Ramo I, Boyd RN, Delgado MR, Gaebler-Spira DJ, Gormley ME, Guyer BM, Heinen F, Holton AF, Matthews D, Molenaers G, Motta F, Garcia Ruiz PJ, Vissel J. (2000) Recommendations for the use of botulinum toxin type A in the management of cerebral palsy. Gait Posture 11: 67-79.
16. Koman LA, Brashear A, Rosenfeld S, Chambers H, Russman B, Rang M, Root L, Ferrari E, Garcia de Yebenes Prous J, Smith BP Turkel C, Walcott JM, Molloy PT. (2001) Botulinum toxin type A neuromuscular blockade in the treatment of equinus foot deformity in cerebral palsy: A multicenter, open-label clinical trial. Pediatrics 108: 1062-1071.
17. Mackie PC, Jessen EC, Jarvis SN. (1998) The lifestyle assessment questionnaire: An instrument to measure the impact of a disability on the lives of children with cerebral palsy and their families. Child Care Health Dev 40: 473-481.
18. McLaughlin JF, Bjornson KF, Astley SJ, Graubert C, Hays RM, Roberts TS, Price R, Temkin N. (1998) Selective dorsal rhizotomy: Efficacy and safety in an investigator-masked randomized clinical trial. Dev Med Child Neurol 40: 220-232.
19. Ottenbacher KJ, Msall ME, Lyon N, Duffy LC, Ziviani J, Granger CV, Braun S, Feidler RC. (2000) The WeeFIM instrument: Its utility in detecting change in children with developmental disabilities. Arch Phys Med Rehabil 81: 1317-1326.
20. Palisano R, Rosenbaum P, Walter S, Russell D, Wood E, Galuppi B. (1997) Development and reliability of a system to classify gross motor function in children with cerebral palsy. Dev Med Child Neurol 39: 214-223.
21. Palisano RJ, Haley SM, Brown DA. (1992) GOAL attainment scaling as a measure of change in infants with motor delay. Phys Ther 72: 432-437.
22. Penn RD, Kroin JS. (1985) Continuous intrathecal baclofen for severe spasticity, Lancet 2: 125-127.
23. Pranzatelli MR. (1996) Oral pharmacotherapy for the movement disorders of cerebral palsy. J Child Neurol 11 (Supp 1): S13-S22.
24. Rosenbaum PL, Saigal S. (1996) Measuring health-related quality of life in pediatric populations: Conceptual issues. In: Spilker B, editor. Quality of Life and Pharmacoeconomics in Clinical Trials. 2nd edn. Philadelphia: Lippencott-Raven. p 785-791.
25. Russell DJ, Avery LM, Rosenbaum PL, Raina PS, Walter SD, Palisano RJ. (2000) Improved scaling of the gross motor function measure for children with cerebral palsy: Evidence of reliability and validity. Phys Ther 80: 873-885.
26. Savoy SM, Gianino JM. (1993) Intrathecal baclofen infusion: An innovative approach for controlling spinal spasticity Rehabil Nurs 18: 105-113.
27. Scheinberg A, O'Flaherty S, Chaseling R, Dexter M. (2001) Continuous intrathecal baclofen infusion for children with cerebral palsy: A pilot study. J Paediatr Child Health 37: 283-288.
28. Schneider JW, Gurucharri LM, Gutierrez AL, Gaebler-Spira DJ. (2001) Health-related quality of life and functional outcome measures for children with cerebral palsy. Dev Med Child Neurol 43: 601-608.
29. Steinbok P, Reiner AM, Beauchamp R, Armstrong RW, Cochrane DD, Kestle J. (1997) A randomized clinical trial to compare selective posterior rhizotomy plus physiotherapy with physiotherapy alone in children with spastic diplegic cerebral palsy. Dev Med Child Neurol 39: 178-184.
30. Streiner DL, Norman GR. (2003) Health measurement scales: A Practical Guide to their Development and Use. 3rd edn. Oxford: Oxford University Press. p 183-184.
31. Van Schaeybroeck P, Nuttin B, Lagae L, Schrijvers E, Borghgraef C, Feys P. (2000) Intrathecal baclofen for intractable cerebral spasticity: A prospective placebo-controlled, double-blind study. Neurosurgery 46: 603-609.
32. Wake M, Salmon L, Reddihough D. (2003) Health status of Australian children with mild to severe cerebral palsy: Cross-sectional survey using the Child Health Questionnaire. Dev Med Child Neurol 45: 194-199.
33. Wright FV, Sheil EM, Drake JM, Wedge JH, Naumann S. (1998) Evaluation of selective dorsal rhizotomy for the reduction of spasticity in cerebral palsy: A randomized controlled trial. Dev Med Child Neurol 40: 239-247.